Floatz logo

Metyrapone

Abdominal Obesity-Metabolic Syndrome

Baker Heart Research InstituteSmall moleculePhase 4 / ApprovedDormant
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
73/ 100

Competitive context

42 Active assets in the Abdominal Obesity-Metabolic Syndrome cohort.

Asset / SponsorPhaseRating
Topiramate
All India Institute of Medical Sciences, Bhubaneswar
Phase 4BBB
Atorvastatin
Seoul National University Hospital
Phase 4BBB
Pioglitazone
Philip Kern
Phase 4BBB
Olmesartan Medoxomil
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Phase 4BBB
Rosuvastatin
Hamdard University
Phase 4BBB

View all 50 →

Same molecule, other indications

Metyrapone is also rated in:

obesity disorderActive
CCC
Indicative · Phase 4
54 / 100
View asset →
adrenal gland hyperfunctionActive
CCC
Indicative · Phase 2
53 / 100
View asset →
major depressive disorderDormant
CCC
Indicative · Phase 2
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →